Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15261373 | 0.93 | PIK3CD (0.58) | POLBPIK3CD | |
| SCHEMBL15139181 | 0.93 | PIK3CD (0.58) | POLBPIK3CD | |
| SCHEMBL2630980 | 0.87 | POLB (0.48) | POLBGPR119PIK3CD | |
| SCHEMBL5267601 | 0.84 | POLB (0.55) | POLBGPR119PIK3CDNPBWR1MCHR1 | |
| SCHEMBL1065920 | 0.82 | GPR119 (0.55) | GPR119PIK3CDNPBWR1MCHR1 | |
| SCHEMBL19329433 | 0.82 | MEN1 (0.48) | POLBGPR119PIK3CDNPBWR1MCHR1 | |
| SCHEMBL13734463 | 0.81 | GPR119 (0.59) | GPR119PIK3CD | |
| SCHEMBL17455992 | 0.81 | GPR119 (0.53) | GPR119 | |
| SCHEMBL31080494 | 0.81 | GPR119 (0.50) | GPR119PIK3CDNPBWR1MCHR1 | |
| SCHEMBL17456045 | 0.81 | POLB (0.43) | POLBGPR119PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982666-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-9598398-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| EP-2982666-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-10 | — | — | EP | disclosed |
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | PSEN1, PSEN2, BACE1 | POLB 4211/4885GPR119 1505/4885PIK3CD 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.